OncLive News Network®

Aditya Bardia, MD, MPH discusses the present and prospective clinical applications of ctDNA monitoring informed by promising data presented at the ASCO 2022 Annual Meeting.

Expert oncologists incorporate personal experience with data from the recent ASCO 2022 annual meeting to highlight optimal testing and management strategies in breast cancer.

Omid Hamid, MD, and Ryan Sullivan, MD, discuss new updates in uveal melanoma, and an exciting, recently approved agent for treatment of metastatic disease.

Expert oncologists reflect on recent clinical trial data to elucidate the evolving treatment landscape of checkpoint inhibition in non–small cell lung cancer.

Experts discuss current and investigational antibody drug conjugates (ADCs) in non-small cell lung cancer treatment and how they affect therapy approaches.

Mark G. Kris, MD, FASCO provides insight on monitoring patients with NSCLC and discusses the developing role of ctDNA.

Vijayakrishna Gadi, MD, PhD, provides an overview of recent advancements in the treatment of HER2+ metastatic breast cancer with special consideration for challenges in the management of patients with CNS metastases.

Jae Park, MD, reviews the current treatment landscape and emerging options for treating adults with relapsed/refractory B-cell acute lymphoblastic leukemia

Join us LIVE at this year's 2022 ASCO Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and gynecologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.

Experts Joyce A. O’Shaughnessy, MD, and Sara A. Hurvitz, MD, provide comprehensive updates on the optimal workup and management of patients with breast cancer.

Expert perspectives on novel management of HER2+ metastatic breast cancer in the context of recent clinical trials and FDA approvals.

Join us LIVE at this year's 2022 Genitourinary Cancers Symposium! OncLive® will broadcast a series of interviews with top thought leaders across cancers of the bladder, prostate, and kidney. The experts will share their insights and reactions to the pivotal data presented during the conference.

How ctDNA testing is being investigated and used in pancreatic and colorectal cancer in the era of precision medicine.

Two experts lead a discussion about chronic lymphocytic leukemia (CLL), focusing on updates in management and special considerations when treating with BTK inhibitors.

Drs Carl M. Gay and Jared Weiss highlight novel treatment advances for newly diagnosed and relapsed/refractory small cell lung cancer.

Hossein Borghaei, DO, MS, and Martin Reck, MD, PhD, highlight recent advances and use of immune checkpoint inhibitors in the treatment of first-line metastatic non-small cell lung cancer.

Shared insight on the clinical impact circulating tumor DNA testing has had on the management of patients with breast cancer.

Gary Ulaner, MD, PhD and Jeremy Force, DO discuss the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18F-FES-PET imaging in diagnosis and treatment of ER-positive breast cancer and in improving patient outcomes.

Experts review key updates in multiple myeloma management from the ASH 2021 annual meeting.

As part of its Speaking Out video series, CURE spoke with Rebecca Moroose, MD, from Orlando Health Cancer Institute, and Virginia G. Kaklamani, MD, from UT Health San Antonio, about the National Comprehensive Cancer Network guidelines and what they mean for patients.

Join us LIVE at this year's 2021 ASH Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders across hematologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.

Experts Sandra M. Swain, MD, and Zahi Mitri, MD, MS, reflect on HER2-low breast cancer as a subset of disease and discuss novel therapeutic agents that may improve patient outcomes in this setting.

Nitin Jain, MD, and Richard R. Furman, MD, review the role of BTK inhibitors and emerging therapies on the horizon for the management of CLL.

Kenneth Shain, MD, PhD reviews advances in treatment of relapsed and refractory multiple myeloma and data presented at 2021 International Myeloma Workshop.

Preferences for conducting molecular testing in patients with chronic lymphocytic leukemia to guide treatment decisions based on evolving novel combination regimens used as frontline therapy.

Expert gynecologic oncologist Rebecca Arend, MD, MPH, addresses data from the 2021 ESMO meeting and the approval of tisotumab vedotin for patients with cervical cancer.

Rebecca Suk Heist, MD, MPH, and Solange Peters, MD, PhD, discuss data updates from the TROPION-PanTumor01 study that impact the use of antibody-drug conjugates as a therapy option for patients with second-line metastatic non-small cell lung cancer.